5 min read
The creation, authorization and distribution of Covid-19 vaccinations is a milestone for science and humanity. However, it will also be a source of income for millionaires for pharmaceutical developers such as: Pfizer and Modernawho could earn close $ 32 billion with the expected drug.
Only that is appreciated In 2021, Pfizer will generate $ 19 billion Coronavirus vaccine revenue, according to Morgan Stanley. That is on top of the estimated 975 million they received from vaccines in 2020.
The same financial entity estimates that Pfizer will earn around $ 9.3 billion more on its vaccine between 2022 and 2023 as mass vaccination continues among the world’s population. The income is shared with BioNTech, the German company it worked with to develop the vaccine.
The actions of Pfizer have increased by 12% this year while that of his partner BioNTech They are up almost 300%. The value of the German biotech company amounted to almost 30 billion US dollars.
Last Friday, December 11th, Mexico became the fifth country to approve Pfizer’s emergency application of the COVID-19 vaccine to the UK, Bahrain, Canada and Saudi Arabia and just hours before the FDA gave the go-ahead for their Application in the United States.
The @ COFEPRIS as a decentralized facility depending on the @Shealth_mxwith administrative, technical and operational autonomy, whose tasks include the approval of health services, communicates the following: https://t.co/ldV2rvYIOr pic.twitter.com/852oHE3ny3
– COFEPRIS (@COFEPRIS) December 12, 2020
Moderna, which benefits the most from its SARS-CoV-2 virus vaccine
Few had heard of it before 2020 Modern, the young biotech company that developed its own coronavirus vaccine in just two days. Now the value of the American pharmaceutical company is estimated at $ 62 billionas their actions skyrocketed 700% this year. Morgan Stanley estimates that about half of the company’s market value is related to the vaccine.
Moderna is expected to be preserved Revenue from the drug of $ 13.2 billion in 2021according to Goldman Sachs. Morgan Stanley said Moderna investors expect the company to raise between $ 10 billion and $ 15 billion in sales of its vaccine in 2021 and 2022, and millions more in the years that follow.
These numbers are especially astonishing when you consider that Moderna only had sales of about $ 60 million in 2019. The company has never licensed a product, but its vaccine made using mRNA technology could be approved by the Food and Drug Administration. of the United States (FDA) on December 17th.
We just announced the US. The government has exercised the first option for an additional 100 million doses of our COVID-19 vaccine candidate, which will be delivered in the second quarter of 2021. Read more: https://t.co/zxznonNRek pic.twitter.com/l2Cs0qYZcM
– Modern (@moderna_tx) December 11, 2020
The results of Pfizer and Moderna are not without controversy
Pharmaceuticals Johnson Johnson and AstraZeneca, who are also developing coronavirus vaccines, have promised that these will be available for nonprofit.
“It is absolutely wrong that pharmaceutical companies like Pfizer and Moderna are benefiting from the COVID-19 vaccines that have been so heavily subsidized and supported by American taxpayers and that their executives make great personal fortunes.”said Eli Zupnick, spokesman for Accountable.US, a progressive patient advocacy group.
Pfizer said the cost of developing and manufacturing the Covid-19 vaccine “You have been entirely self-funded and billions of dollars are already at risk.”Read a statement posted last month. “The company will continue to bear all development and manufacturing costs to find a solution to this pandemic as soon as possible.”.
See also: Bill Gates predicts when the pandemic will end
With information from Cnn in Spanish.